Managing metabolic health through the gut microbiome

Date & Time
Continuing Education (USA)
Duration1 hour
CPEUs Awarded1
Performance Indicators8.3.1, 8.3.6, 8.3.7
US dietitians: 1.0 CE credit from CDRCPD hours are applicable for Australia and New Zealand dietitians. To obtain your CEU certificate/certificate of attendance, click the ‘Get it now’ button and follow the prompts to register. Then go to your Dashboard on your Dietitian Connection account and download the certificate for this webinar.

About the webinar:

Research is revealing an in-depth understanding of the role of numerous microbial metabolites in the pathogenesis of metabolic diseases, such as cardiovascular disease, diabetes, non-alcoholic fatty liver disease and obesity. This webinar will provide a summary of the current body of evidence with a focus on clinically relevant evidence-based strategies to modify these microbial risk factors. Ultimately, Dietitians will be guided on how to use microbiome profiling to guide personalised interventions for the prevention and management of metabolic disease.


About the speakers:


Anita Tait is an Accredited Practising Dietitian and Pharmacologist and has worked within corporate health, food industry and the pharmaceutical industry for the past 10-years. Anita works as an APD in two Brisbane clinics and specialises in Gastrointestinal Disorders. She also works at Microba where she is involved in supporting Dietitians in the clinical utility of microbiome analysis in practice.





 Dr Paula Smith-Brown PhD is the Lead Dietitian at Microba. The importance of the microbiome in the interface between diet and metabolism first became apparent to her back in the early days of her PhD in 2011. She initially intended to use metabolomics to explore how diet impacts metabolism but soon realised that every metabolite being linked to diet in the literature was microbial in origin. This realisation led her to completely redesign her PhD to focus on the links between diet and the microbiome. Over the last decade she has watched the exponential growth in the body of evidence available to understanding the role of the microbiome in the management of metabolic disease and is excited we have now reached the point when this evidence can begin to be translated into clinical practice.


Supported by